Seattle Genetics Inc.
) recently commenced two phase I clinical studies with its
oncology candidate, SGN-CD19A. The two trials will assess the
safety and anti-tumor response of SGN-CD19A in CD19-positive
acute lymphoblastic leukemia (ALL) and B-cell non-Hodgkin
lymphoma (HL) patients.
Establishing the maximum tolerated dose and examining the
safety of the candidate are the two primary endpoints of the
trials. The trials will also assess antitumor activity,
pharmacokinetics, progression-free survival (PFS) and overall
According to the American Cancer Society, more than 70,000
cases of non-HL and roughly 6,000 cases of ALL were expected to
be diagnosed in the US during 2012 and almost 19,000 people were
expected to die from non-HL and more than 1,400 were expected to
die from ALL.
Meanwhile, Adcetris recently received approval under Health
Canada's Notice of Compliance with conditions (NOC/c) for the
treatment of relapsed or refractory HL and systemic anaplastic
large cell lymphoma (sALCL).
For similar indications, Adcetris was approved by the US Food and
Drug Administration (FDA) in Aug 2011 and in the EU in Oct 2012.
Adcetris, Seattle Genetics' only approved drug, generated
revenues of $102.8 million for the nine months ending Sep 30,
In Jan 2013, a global phase III study (ECHELON-2) was
initiated on Adcetris. In this study, Adcetris plus chemotherapy
will be evaluated for the front-line treatment of CD30-positive
mature T-cell lymphoma (MTCL) including patients with sALCL and
other types of peripheral T-cell lymphomas.
Seattle Genetics currently carries a Zacks Rank #4 (Sell).
Peregrine Pharmaceuticals, Inc.
) look more attractive with a Zacks Rank #1 (Strong Buy).
AGENUS INC (AGEN): Free Stock Analysis Report
PEREGRINE PHARM (PPHM): Free Stock Analysis
SEATTLE GENETIC (SGEN): Free Stock Analysis
TARGACEPT INC (TRGT): Free Stock Analysis
To read this article on Zacks.com click here.